KidsMD Health Topics

Leiomyosarcoma in Children

  • If your child has been diagnosed with leiomyosarcoma, you’ll have concerns and questions about her health, treatment, recovery and other issues. It may comfort you to know that leiomyosarcoma is a very rare, but very treatable cancer, and that Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is a world leader in treating children with cancer. We specialize in innovative, family-centered care that supports your child and family every step of the way.

    About leiomyosarcoma

    Leiomyosarcomais a very rare, but very treatable cancer. It’s a type of soft tissue sarcoma (cancer) that grows in muscle tissue in muscles, including muscles in the skin and organs. In children, it usually grows in the gastrointestinal tract. Since it is in the soft tissue areas, it can be difficult to detect because they are covered by other structures such as skeletal muscle.

    • Leiomyosarcoma can spread (metastasize) to other areas of the body, but usually does not if it is removed early.
    • Its cause is unknown but has been linked to genetics and inherited diseases.
    • Children with AIDS are at risk for developing this kind of cancer.
    • A tumor may exist for a long time before being discovered.
    • Treatment usually involves surgery and potentially radiation and/or chemotherapy.
    • Leiomyosarcoma is very treatable, with 80% success rate if the tumor is completely removed.
    • There are no gender related risks among children. Girls and boys have equal risks of having leiomyosarcoma.
    • It is extremely rare. There are only 20 to 30 cases of child leiomyosarcoma cases per year in the United States.
    • The outlook is very good if the tumor is completely removed.

    How Dana-Farber/Boston Children’s Cancer and Blood Disorders Center approaches leiomyosarcoma

    Dana-Farber/Boston Children’s Cancer and Blood Disorders Center provides compassionate, comprehensive medical and surgical care for children and adolescents with benign or malignant soft tissue tumors.

    Our multidisciplinary approach to care ensures in-depth discussion of each case and personalized treatment plans for every patient. We integrate expertise from the following specialists:

    In addition to a multidisciplinary approach, we are starting a personalized medicine approach to make sure we treat each leiomyosarcoma case separately, as each person is unique, down to the molecular level. We develop a treatment plan specifically designed for your child.


    Leiomyosarcoma: Reviewed by Carlos Rodriguez-Galindo, MD © Boston Children’s Hospital; posted in 2012

Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fields

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
close
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
BrowseSearch
Condition & Treatments
Search for a Condition or Treatment:
Show Items Starting With: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
View allSearch
Locations
Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Contact Dana-Farber/ Boston Children's

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close